Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients

References

• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115-32; PMID:26808342; https://doi.org/10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Eastern cooperative oncology group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8; PMID:11784875; https://doi.org/10.1056/NEJMoa011954
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57; PMID:19692680; https://doi.org/10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-88; PMID:20573926; https://doi.org/10.1056/NEJMoa0909530
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-8; PMID:20022809; https://doi.org/10.1016/S1470-2045(09)70364-X
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12:735-42; PMID:21783417; https://doi.org/10.1016/S1470-2045(11)70184-X
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-46; PMID:22285168; https://doi.org/10.1016/S1470-2045(11)70393-X
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327-34; PMID:23816960; https://doi.org/10.1200/JCO.2012.44.2806
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15:213-22; PMID:24439929; https://doi.org/10.1016/S1470-2045(13)70604-1
   PubMed Web of Science ®Google Scholar
• Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, Gao G, Shi J, Ren S, Chu H, et al. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol. 2015; 10:778-83; PMID:25629635; https://doi.org/10.1097/JTO.0000000000000487
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012; 18:1947-53; PMID:22317764; https://doi.org/10.1158/1078-0432.CCR-11-2511
   PubMed Web of Science ®Google Scholar
• Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010; 28:4616-20; PMID:20855837; https://doi.org/10.1200/JCO.2010.29.6038
   PubMed Web of Science ®Google Scholar
• Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 2013; 79:8-13; PMID:23098378; https://doi.org/10.1016/j.lungcan.2012.09.018
   PubMed Web of Science ®Google Scholar
• An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, et al. Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status. PLoS One 2012; 7:e40109; PMID:22768234; https://doi.org/10.1371/journal.pone.0040109
   PubMed Web of Science ®Google Scholar
• Qiong Z, Na WY, Bo W, Zhu Z, Ling P, Bo MH, Min TY, Lei Z, Na HD, Bo Z, Fang LJ, Seng ZS. Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. Lung Cancer 2015; 87:117-21; PMID:25488863; https://doi.org/10.1016/j.lungcan.2014.11.011
   PubMed Web of Science ®Google Scholar
• Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012; 13:e418-26; PMID:23026827; https://doi.org/10.1016/S1470-2045(12)70291-7
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, et al. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest 2014; 145:473-9; PMID:24158231; https://doi.org/10.1378/chest.12-2679
   PubMed Web of Science ®Google Scholar
• Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, Gao G, Shi J, Ren S, Chu H, et al. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol 2015; 10:778-83; PMID:25629635; https://doi.org/10.1097/JTO.0000000000000487
   PubMed Web of Science ®Google Scholar
• Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, et al. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol 2014; 9:760-8; PMID:24481316; https://doi.org/10.1097/JTO.0b013e3182a406d1
   PubMed Web of Science ®Google Scholar
• Toyooka S, Yatabe Y, Tokumo M, Ichimura K, Asano H, Tomii K, Aoe M, Yanai H, Date H, Mitsudomi T, Shimizu N. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006; 118:1588-90; PMID:16187277; https://doi.org/10.1002/ijc.21500
   PubMed Web of Science ®Google Scholar
• Wang J, Shen Q, Shi Q, Yu B, Wang X, Cheng K, Lu G, Zhou X. Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry. J Exp Clin Cancer Res 2014; 33:109; PMID:25527865; https://doi.org/10.1186/s13046-014-0109-2
   PubMedGoogle Scholar
• Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M.ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer 2016; 94:22-7; PMID:26973202; https://doi.org/10.1016/j.lungcan.2016.01.011
   PubMed Web of Science ®Google Scholar
• Mikes RE, Jordan F, Hutarew G, Studnicka M. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. Lung Cancer. 2015; 90:614-6; PMID:26519123; https://doi.org/10.1016/j.lungcan.2015.10.013
   PubMed Web of Science ®Google Scholar
• Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 2014; 83:109-11; PMID:24192513; https://doi.org/10.1016/j.lungcan.2013.10.006
   PubMed Web of Science ®Google Scholar
• Lin C, Wang S, Xie W, Chang, Gan Y. The RET Fusion Gene and Its Correlation with Demographic and Clinicopathological Features of Non-Small Cell Lung Cancer: A Meta-Analysis. Cancer Biol Ther 2015; 16:1019-28; PMID:25975578; https://doi.org/10.1080/15384047.2015.1046649
   PubMed Web of Science ®Google Scholar